TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: remifentanil consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intraoperative heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of Metabolic Syndrome (MBO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of renal calculi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Household satisfaction with CBHI scheme
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean HbA1c levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c targets of <7.0 %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HbA1c targets of ≤6.5 %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Referral for assistance for maternal depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressed mood in mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Signs of anhedonia in mothers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: immune function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fracture healing acceleration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective treatment (mycologic cure and symptom improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: peak plasma glucose concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: insulin area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: peak insulin secretion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Stone-free status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Hypocitraturia levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Cumulative incidence of monotherapy failure at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Weight gain and edema
Endpoint domain: Adverse events/effects
Primary endpoint: Fat consumption reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increased fruit and vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Behavioral measure of fat consumption reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: FNHTR rate for PP transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: Superior mesenteric artery (SMA) blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: decreased muscle protein breakdown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fruit and vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: ET-1 levels improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resting systolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Low frequency: high frequency area ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: LVM index regression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor necrosis and viable cell content in the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Alpha-fetoprotein and Glypican-3 expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Natural killer (NK) cell surface markers and parameters influencing NK cell activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pruritus levels
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of macroangiopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma SAA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: days with correct number of doses taken
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: correct interdose intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postural control on unstable surfaces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MN frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: K-BDI scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of hump
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: E'/A' ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cost per screen
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Major complications or death within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Verbal creativity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wisconsin Card Sorting Test (WCST) performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Bladder-preservation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: TNW (Total Number of Words)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NDW (Number of Different Words)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MLCUm (Mean Length of Communication Units)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3-4 hematologic toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of children with PONV during 0-48 hours after anesthesia
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of cervical adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proximal contacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of color stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crown height changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Facial volume changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unhealthy food consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body Fat (BF) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body Mass Index (BMI) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean triglyceride level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants reporting UAI with nonprimary partners of unknown or discordant HIV status
Endpoint domain: Adverse events/effects
Primary endpoint: Microbiologic eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse of symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients experiencing neurologic decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: percentage of total quality embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of quality blastocysts transferred
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic hypoglycemia
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate to citalopram treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food avoidance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physical disability scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 1-month mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Striatal binding ratio of (123)I-FP-CIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Thalamic binding ratio of (123)I-FP-CIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urine screening negative for opiates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: myocardial gadolinium enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean losses of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Unplanned hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Clinical improvement measured by MLWHFQ
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical improvement measured by NYHA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NIHSS scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in GSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acquisition of CRE
Endpoint domain: Adverse events/effects
Primary endpoint: Acquisition of FCRE
Endpoint domain: Adverse events/effects
Primary endpoint: hypoglycaemia incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incontinent events per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pad use per 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: electrophysiological brain maturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevent youth smoking initiation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Help smokers to quit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastrointestinal treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incontinence for liquid stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: End‐diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PTSS severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PROMIS T-score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 90-day hospital readmission
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: No cases of amyloid‐related imaging abnormalities (ARIA‐E/H)
Endpoint domain: Adverse events/effects
Primary endpoint: CSF concentrations of Aβ X‐38 and Aβ X‐42
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Prostate-specific antigen density (PSAD) classification accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average distance between CT imaging and real-time mapping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal distance between day 1 and day 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thromboxane B(2) levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: dominant-band dexterity for picking up small objects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of bacterial species
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phylogenetic diversity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean satisfaction for the physical environmental intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean satisfaction for the social environmental intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Freedom from arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clearance of unbound platinum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-assessed improvement of pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Drop in peak flow rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: shoulder rotational range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: number of days of abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CTRS total score improvement ≥25%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CTRS inattention/cognitive subscale improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emesis
Endpoint domain: Adverse events/effects
Primary endpoint: Overall effective rate (OER)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular surface disease index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: exclusive breastfeeding (EBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: consumption of iron and folic acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: number of food groups consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Owner assessment of chronic pain using the CBPI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of lameness using FPGA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of stroke risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of talipes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction of thrombus size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in CPRS‐R:L oppositional subscale scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of osteomyelitis
Endpoint domain: Adverse events/effects
Primary endpoint: Glucose-lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Offset of exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Mortality after stroke
Endpoint domain: Mortality/survival
Primary endpoint: Diminished umami taste
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desire for savory foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intake of savory foods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local damage induced by therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hypoglycemia event rate
Endpoint domain: Adverse events/effects
Primary endpoint: Post-inflammatory hyperpigmentation (PIH) incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Completion rates of allocated screening tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of colorectal adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Effectiveness of computer-based training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sputum microbial density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cerebral blood flow improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of cerebral hemorrhage
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of cerebral ischemia
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of DCVS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chinese medicine syndrome score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mycological cure rate against dermatophytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of motoric function at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to get up from bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to walk around
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lumbopelvic movement control performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery without antibiotics
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complications detected on CT scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough reflex response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Narrowing of the glottic aperture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appreciation of visit and feedback
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Neutropenia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Infusion-related symptoms incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Switching treatment due to toxic reactions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: neural activity within the reward system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of OAB symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of abstinence at 2-week follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: craving intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: craving frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: craving duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Good neurologic function (GOS 4-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in HAMD(17) total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated probabilities of remission at week 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute treatment-emergent sexual dysfunction
Endpoint domain: Adverse events/effects
Primary endpoint: Postvoid residual urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of postoperative hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of advancement to full enteral feeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gross Motor Function (GMFM-88)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Tone (MAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cocaine craving ratings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean plasma levels of IGF‐I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: mean plasma levels of IGF‐I/IGFBP‐3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 75th percentile of GH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma concentrations of (R)‐carvedilol and (S)‐carvedilol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentrations of tramadol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean concentrations of metabolite M1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the acellular pertussis vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: radiographic pneumonia risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Screening for colorectal cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall incidence of vomiting
Endpoint domain: Adverse events/effects